Skip to main content
. Author manuscript; available in PMC: 2019 Oct 4.
Published in final edited form as: Clin Cancer Res. 2016 Aug 9;23(4):918–924. doi: 10.1158/1078-0432.CCR-16-1012

Table 2.

Dose escalation of irinotecan and observed DLTs in patients treated with FOLFIRI plus bevacizumab.

Irinotecan dose (mg/m2) *1/*1 patients (DLTs) *1/*28 patients (DLTs)
260 10 (1)
Grade 3 diarrhea
10 (2)
Grade 3 arrythmia
Grade 4 neutropenia
310 10 (2)
Grade 3 diarrhea x 2
10 (4)
Grade 3 diarrhea
Grade 3 mucositis
Grade 4 neutropenia x 2
370 4 (2)
Grade 3 nausea/vomiting
Grade 5 neutropenic sepsis
3 (2)
Grade 3 diarrhea
Grade 4 neutropenia x 2